Loading…
Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review
Energy homeostasis is achieved by the integration of peripheral metabolic signals by the neural circuits involving specific hypothalamic nuclei and brain stem regions. These neural circuits mediate many of the effects of the adipocyte-derived hormone leptin and gut-derived hormone ghrelin. The forme...
Saved in:
Published in: | Schizophrenia bulletin 2008-11, Vol.34 (6), p.1189-1199 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43 |
---|---|
cites | cdi_FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43 |
container_end_page | 1199 |
container_issue | 6 |
container_start_page | 1189 |
container_title | Schizophrenia bulletin |
container_volume | 34 |
creator | Sentissi, Othman Epelbaum, Jacques Olié, Jean-Pierre Poirier, Marie-France |
description | Energy homeostasis is achieved by the integration of peripheral metabolic signals by the neural circuits involving specific hypothalamic nuclei and brain stem regions. These neural circuits mediate many of the effects of the adipocyte-derived hormone leptin and gut-derived hormone ghrelin. The former is strongly anorexigenic while the latter is the only orexigenic agent active when administered by a peripheral route. Abnormal regulation of these 2 antagonistic regulatory peptides in patients with schizophrenia could play a role in the impairment in the regulation of food intake and energy balance. This bibliographical analysis aims to compare 27 prospective and cross-sectional studies published on circulating leptin and ghrelin levels during acute and chronic administration of antipsychotics treatment, especially atypical ones. Fasting morning leptin levels of schizophrenic patients increase rapidly in the first 2 weeks after atypical antipsychotic (AAP) treatment (mostly olanzapine and clozapine) and remain somehow elevated after that period up to several months. On the contrary, conventional antipsychotics (such as haloperidol) do not interfere with leptin levels. In contrast to leptin, fasting morning ghrelin levels decrease during the first few weeks after the beginning of AAPs treatment while they increase in the longer run. Surprisingly, body weight gain and correlations between the variation of these 2 peptides and adiposity and metabolism-related parameters such as the body mass index and abdominal perimeter were not systematically considered. Finally, an objective evaluation of feeding behavior during antipsychotic treatment remains to be determined. |
doi_str_mv | 10.1093/schbul/sbm141 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2632509</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/schbul/sbm141</oup_id><sourcerecordid>1575905961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43</originalsourceid><addsrcrecordid>eNqFkc2LFDEQxYMo7jh69CpBELy0m69Ouj0Iw-66CgOKrngM6UxlO0tPuk3SI-tfv5EeVj15qqLej6pHPYSeU_KGkpafJtt383Cauj0V9AFaUSXqiipCH6IVqRtZKUnFCXqS0g0hVLSSPUYntKGyZpKt0LCFKfuATdjhyz7CUPotHGBIuHSfTfYQcsLffe7xV9v7X-NUqOANPp-jD9f43DsHZZLxJmQ_pVvbj9nbhK8imLwvwlu8wV_g4OHnU_TImSHBs2Ndo2_vL67OPlTbT5cfzzbbygpV54q5VrWupXXbsRrUjhlJlQTXNLITO-ukI5xLSQCU48woxazqKONWOGeNFXyN3i17p7nbw84WE9EMeop-b-KtHo3X_yrB9_p6PGgmOavLV9fo5XFBHH_MkLK-GecYimfNGK9F2zBVoGqBbBxTiuDuD1Cif2ejl2z0kk3hX_zt6g99DKMAr46ASdYMLppgfbrnGGk455QX7vXCjfP0n5t3CTqpjQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223549827</pqid></control><display><type>article</type><title>Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review</title><source>Open Access: PubMed Central</source><source>Oxford Journals Online</source><creator>Sentissi, Othman ; Epelbaum, Jacques ; Olié, Jean-Pierre ; Poirier, Marie-France</creator><creatorcontrib>Sentissi, Othman ; Epelbaum, Jacques ; Olié, Jean-Pierre ; Poirier, Marie-France</creatorcontrib><description>Energy homeostasis is achieved by the integration of peripheral metabolic signals by the neural circuits involving specific hypothalamic nuclei and brain stem regions. These neural circuits mediate many of the effects of the adipocyte-derived hormone leptin and gut-derived hormone ghrelin. The former is strongly anorexigenic while the latter is the only orexigenic agent active when administered by a peripheral route. Abnormal regulation of these 2 antagonistic regulatory peptides in patients with schizophrenia could play a role in the impairment in the regulation of food intake and energy balance. This bibliographical analysis aims to compare 27 prospective and cross-sectional studies published on circulating leptin and ghrelin levels during acute and chronic administration of antipsychotics treatment, especially atypical ones. Fasting morning leptin levels of schizophrenic patients increase rapidly in the first 2 weeks after atypical antipsychotic (AAP) treatment (mostly olanzapine and clozapine) and remain somehow elevated after that period up to several months. On the contrary, conventional antipsychotics (such as haloperidol) do not interfere with leptin levels. In contrast to leptin, fasting morning ghrelin levels decrease during the first few weeks after the beginning of AAPs treatment while they increase in the longer run. Surprisingly, body weight gain and correlations between the variation of these 2 peptides and adiposity and metabolism-related parameters such as the body mass index and abdominal perimeter were not systematically considered. Finally, an objective evaluation of feeding behavior during antipsychotic treatment remains to be determined.</description><identifier>ISSN: 0586-7614</identifier><identifier>EISSN: 1745-1701</identifier><identifier>DOI: 10.1093/schbul/sbm141</identifier><identifier>PMID: 18165262</identifier><identifier>CODEN: SCZBB3</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Antipsychotics ; Appetite - drug effects ; Biological and medical sciences ; Body Weight - drug effects ; Cross-Sectional Studies ; Drug toxicity and drugs side effects treatment ; Eating - drug effects ; Energy Metabolism - drug effects ; Female ; Ghrelin - blood ; Homeostasis - drug effects ; Humans ; Leptin - blood ; Male ; Medical sciences ; Middle Aged ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Pharmacology. Drug treatments ; Prospective Studies ; Regular ; Schizophrenia - blood ; Schizophrenia - drug therapy ; Young Adult</subject><ispartof>Schizophrenia bulletin, 2008-11, Vol.34 (6), p.1189-1199</ispartof><rights>Published by Oxford University Press 2007. 2008</rights><rights>2009 INIST-CNRS</rights><rights>Published by Oxford University Press 2007.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43</citedby><cites>FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2632509/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2632509/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20833313$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18165262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sentissi, Othman</creatorcontrib><creatorcontrib>Epelbaum, Jacques</creatorcontrib><creatorcontrib>Olié, Jean-Pierre</creatorcontrib><creatorcontrib>Poirier, Marie-France</creatorcontrib><title>Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review</title><title>Schizophrenia bulletin</title><addtitle>Schizophr Bull</addtitle><description>Energy homeostasis is achieved by the integration of peripheral metabolic signals by the neural circuits involving specific hypothalamic nuclei and brain stem regions. These neural circuits mediate many of the effects of the adipocyte-derived hormone leptin and gut-derived hormone ghrelin. The former is strongly anorexigenic while the latter is the only orexigenic agent active when administered by a peripheral route. Abnormal regulation of these 2 antagonistic regulatory peptides in patients with schizophrenia could play a role in the impairment in the regulation of food intake and energy balance. This bibliographical analysis aims to compare 27 prospective and cross-sectional studies published on circulating leptin and ghrelin levels during acute and chronic administration of antipsychotics treatment, especially atypical ones. Fasting morning leptin levels of schizophrenic patients increase rapidly in the first 2 weeks after atypical antipsychotic (AAP) treatment (mostly olanzapine and clozapine) and remain somehow elevated after that period up to several months. On the contrary, conventional antipsychotics (such as haloperidol) do not interfere with leptin levels. In contrast to leptin, fasting morning ghrelin levels decrease during the first few weeks after the beginning of AAPs treatment while they increase in the longer run. Surprisingly, body weight gain and correlations between the variation of these 2 peptides and adiposity and metabolism-related parameters such as the body mass index and abdominal perimeter were not systematically considered. Finally, an objective evaluation of feeding behavior during antipsychotic treatment remains to be determined.</description><subject>Adult</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Appetite - drug effects</subject><subject>Biological and medical sciences</subject><subject>Body Weight - drug effects</subject><subject>Cross-Sectional Studies</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Eating - drug effects</subject><subject>Energy Metabolism - drug effects</subject><subject>Female</subject><subject>Ghrelin - blood</subject><subject>Homeostasis - drug effects</subject><subject>Humans</subject><subject>Leptin - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Regular</subject><subject>Schizophrenia - blood</subject><subject>Schizophrenia - drug therapy</subject><subject>Young Adult</subject><issn>0586-7614</issn><issn>1745-1701</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqFkc2LFDEQxYMo7jh69CpBELy0m69Ouj0Iw-66CgOKrngM6UxlO0tPuk3SI-tfv5EeVj15qqLej6pHPYSeU_KGkpafJtt383Cauj0V9AFaUSXqiipCH6IVqRtZKUnFCXqS0g0hVLSSPUYntKGyZpKt0LCFKfuATdjhyz7CUPotHGBIuHSfTfYQcsLffe7xV9v7X-NUqOANPp-jD9f43DsHZZLxJmQ_pVvbj9nbhK8imLwvwlu8wV_g4OHnU_TImSHBs2Ndo2_vL67OPlTbT5cfzzbbygpV54q5VrWupXXbsRrUjhlJlQTXNLITO-ukI5xLSQCU48woxazqKONWOGeNFXyN3i17p7nbw84WE9EMeop-b-KtHo3X_yrB9_p6PGgmOavLV9fo5XFBHH_MkLK-GecYimfNGK9F2zBVoGqBbBxTiuDuD1Cif2ejl2z0kk3hX_zt6g99DKMAr46ASdYMLppgfbrnGGk455QX7vXCjfP0n5t3CTqpjQ</recordid><startdate>20081101</startdate><enddate>20081101</enddate><creator>Sentissi, Othman</creator><creator>Epelbaum, Jacques</creator><creator>Olié, Jean-Pierre</creator><creator>Poirier, Marie-France</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope></search><sort><creationdate>20081101</creationdate><title>Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review</title><author>Sentissi, Othman ; Epelbaum, Jacques ; Olié, Jean-Pierre ; Poirier, Marie-France</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Appetite - drug effects</topic><topic>Biological and medical sciences</topic><topic>Body Weight - drug effects</topic><topic>Cross-Sectional Studies</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Eating - drug effects</topic><topic>Energy Metabolism - drug effects</topic><topic>Female</topic><topic>Ghrelin - blood</topic><topic>Homeostasis - drug effects</topic><topic>Humans</topic><topic>Leptin - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Regular</topic><topic>Schizophrenia - blood</topic><topic>Schizophrenia - drug therapy</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sentissi, Othman</creatorcontrib><creatorcontrib>Epelbaum, Jacques</creatorcontrib><creatorcontrib>Olié, Jean-Pierre</creatorcontrib><creatorcontrib>Poirier, Marie-France</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Schizophrenia bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sentissi, Othman</au><au>Epelbaum, Jacques</au><au>Olié, Jean-Pierre</au><au>Poirier, Marie-France</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review</atitle><jtitle>Schizophrenia bulletin</jtitle><addtitle>Schizophr Bull</addtitle><date>2008-11-01</date><risdate>2008</risdate><volume>34</volume><issue>6</issue><spage>1189</spage><epage>1199</epage><pages>1189-1199</pages><issn>0586-7614</issn><eissn>1745-1701</eissn><coden>SCZBB3</coden><abstract>Energy homeostasis is achieved by the integration of peripheral metabolic signals by the neural circuits involving specific hypothalamic nuclei and brain stem regions. These neural circuits mediate many of the effects of the adipocyte-derived hormone leptin and gut-derived hormone ghrelin. The former is strongly anorexigenic while the latter is the only orexigenic agent active when administered by a peripheral route. Abnormal regulation of these 2 antagonistic regulatory peptides in patients with schizophrenia could play a role in the impairment in the regulation of food intake and energy balance. This bibliographical analysis aims to compare 27 prospective and cross-sectional studies published on circulating leptin and ghrelin levels during acute and chronic administration of antipsychotics treatment, especially atypical ones. Fasting morning leptin levels of schizophrenic patients increase rapidly in the first 2 weeks after atypical antipsychotic (AAP) treatment (mostly olanzapine and clozapine) and remain somehow elevated after that period up to several months. On the contrary, conventional antipsychotics (such as haloperidol) do not interfere with leptin levels. In contrast to leptin, fasting morning ghrelin levels decrease during the first few weeks after the beginning of AAPs treatment while they increase in the longer run. Surprisingly, body weight gain and correlations between the variation of these 2 peptides and adiposity and metabolism-related parameters such as the body mass index and abdominal perimeter were not systematically considered. Finally, an objective evaluation of feeding behavior during antipsychotic treatment remains to be determined.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>18165262</pmid><doi>10.1093/schbul/sbm141</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0586-7614 |
ispartof | Schizophrenia bulletin, 2008-11, Vol.34 (6), p.1189-1199 |
issn | 0586-7614 1745-1701 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2632509 |
source | Open Access: PubMed Central; Oxford Journals Online |
subjects | Adult Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Antipsychotics Appetite - drug effects Biological and medical sciences Body Weight - drug effects Cross-Sectional Studies Drug toxicity and drugs side effects treatment Eating - drug effects Energy Metabolism - drug effects Female Ghrelin - blood Homeostasis - drug effects Humans Leptin - blood Male Medical sciences Middle Aged Miscellaneous (drug allergy, mutagens, teratogens...) Pharmacology. Drug treatments Prospective Studies Regular Schizophrenia - blood Schizophrenia - drug therapy Young Adult |
title | Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T06%3A40%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Leptin%20and%20Ghrelin%20Levels%20in%20Patients%20With%20Schizophrenia%20During%20Different%20Antipsychotics%20Treatment:%20A%20Review&rft.jtitle=Schizophrenia%20bulletin&rft.au=Sentissi,%20Othman&rft.date=2008-11-01&rft.volume=34&rft.issue=6&rft.spage=1189&rft.epage=1199&rft.pages=1189-1199&rft.issn=0586-7614&rft.eissn=1745-1701&rft.coden=SCZBB3&rft_id=info:doi/10.1093/schbul/sbm141&rft_dat=%3Cproquest_pubme%3E1575905961%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-2f979f9159b25e7d2a6176ef886b4dcf6f033660ee7f32a772c7b123c4ffcac43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=223549827&rft_id=info:pmid/18165262&rft_oup_id=10.1093/schbul/sbm141&rfr_iscdi=true |